Ergoloid mesylates
From Wikipedia, the free encyclopedia
(Redirected from Hydergine)
| Image:Ergoloid mesylates.png | |
| Ergoloid mesylates
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | 8067-24-1 |
| ATC code | C04AE01 |
| PubChem | 592735 |
| DrugBank | APRD00711 |
| Chemical data | |
| Formula | C33H45N5O5 |
| Mol. weight | 591.741 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98-99% |
| Metabolism | ? |
| Half life | 3.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ergoloid mesylates (Brand names: Hydergine, Gerimal, Niloric, Redizork) (Chemical name: Dihydroergotoxine mesylate) are dihydrogenated ergot alkaloids used to combat decreased mental function as a result of senility or multiple small strokes.
While the exact method of its action is not known, dihydroergotoxine stimulates dopaminergic and serotoninergic receptors and blocks alpha-adrenoreceptors. It is a nootropic.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Developer & Producers: Albert Hofmann for Sandoz (now part of Novartis)
Sizes: 4,5mg p/T (x30) or 1,5mg p/T
Agent: dihydroergotoxin mesylate
